Abstract:CD36 plays a critical role in lipid metabolism, which is closely associated with human immunity. However, the role of CD36 in cancer remains unclear. We performed a pan-cancer analysis to elucidate the potential role of CD36 in cancer by investigating its prognostic value and current predictors for the efficacy of immune checkpoint inhibitors (ICIs) in multiple cancer types. CD36 expression in cancer cell lines, tumor tissue, and their adjacent normal tissues displayed heterogeneity among different cancers. Immunohistochemistry was used to detect CD36 expression and confirmed the results. CD36 expression significantly affects prognosis in the six cancer types. High CD36 expression was marginally associated with poorer prognosis in four of them and improved prognosis in the remaining two types. CD36 expression was significantly correlated with the 6 immune infiltrates in most cancer types. In addition, CD36 gene expression was positively correlated with Stromal score, Immune score, and ESTIMATE score. A total of 47 immune checkpoint genes were collected and their relationship with CD36 expression was analyzed. CD36 expression was significantly associated with multiple stimulatory and inhibitory checkpoint molecules with a disease-specific pattern. As to the genes reported to positively relate to the efficacy of ICIs, CD36 expression was positively correlated with most of them but negatively associated with a small proportion of cancer type-specific patterns. Concerning the genes negatively related to the efficacy of ICIs, CD36 expression was positively correlated with NRP1 and TNFSF15 in multiple cancers. CD36 expression was negatively correlated with tumor neoantigen burden in most cancer types. However, CD36 expression was negatively correlated with tumor mutation burden in most cancer types. The correlation between CD36 expression and the four methyltransferases was also significant in multiple cancers, but also with a cancer type-specific pattern. In summary, the current study found CD36 expression and its prognostic value in multiple cancer types. In addition, the expression of CD36 was significantly associated with current predictors for the efficacy of ICIs. The practical application value of CD36 is disease specific.

Unveiling the hidden role of the interaction between CD36 and FcγRIIb: implications for autoimmune disorders

B-cell Receptor Repertoire Sequencing: Deeper Digging into the Mechanisms and Clinical Aspects of Immune-Mediated Diseases

CD36 and Its Role in Regulating the Tumor Microenvironment

CD36, a signaling receptor and fatty acid transporter that regulates immune cell metabolism and fate

CD36 and LC3B initiated autophagy in B cells regulates the humoral immune response

CD36 and Atherosclerosis

CD36, a Scavenger Receptor Involved in Immunity, Metabolism, Angiogenesis, and Behavior

Interplay of CD36, autophagy, and lipid metabolism: insights into cancer progression

The regulatory role of CD36 in hematopoiesis beyond fatty acid uptake

The function of CD36 in Mycobacterium tuberculosis infection

CD 36: Focus on Epigenetic and Post-Transcriptional Regulation

CD36 Signal Transduction in Metabolic Diseases: Novel Insights and Therapeutic Targeting

Role of CD36 in central nervous system diseases

Prognostic and immunological role of CD36: A pan-cancer analysis

Monocyte CD36 Expression Predicts Disease Activity in Patients With Crohn's Disease

Role of the CXCR6/CXCL16 axis in autoimmune diseases

CD300e: Emerging role and mechanism as an immune-activating receptor

Efferocytosis: Unveiling its potential in autoimmune disease and treatment strategies

CD36 in Atherosclerosis: Pathophysiological Mechanisms and Therapeutic Implications

CD36: a promising therapeutic target in hematologic tumors

FcγRIIB-mediated dissociation of BCR-CD19 microclusters and hyperreactivity of lupus B cells (HUM7P.303)